This trial is completed!
Search for a recruiting clinical trial for your condition
You can access this
clinical trial
if you have
Diabetes, Diabetes Mellitus, Type 2 or Healthy
and you are a man who is
between 18 and 55
years old
Phase
1
This is an early phase trial to determine
the dosage and safety of the new treatment.
Show me locations

The purpose

This trial is conducted in Europe. The aim of this trial is to investigate the safety, tolerability, pharmacokinetics (exposure of drug) and pharmacodynamics (effect of drug) of NNC 0148-0000-0362 as tablets in healthy volunteers. The trial consists of two parts. In part 1, single escalating doses of NNC 0148-0000-0362, placebo or insulin glargine is given. In part 2, subjects will receive single doses of NNC 0148-0000-0362 administered orally or intravenously.

Provided treatments

  • Drug: NNC 0148-0000-0362
  • Drug: insulin glargine
  • Drug: placebo
  • Drug: NNC 0148-0000-0362
  • Drug: NNC 0148-0000-0362
  • Drug: NNC 0148-0000-0362
Tris trial is registered with FDA with number: NCT01597713. The sponsor of the trial is Novo Nordisk A/S and it is looking for 83 volunteers for the current phase.
Official trial title:
A Trial Investigating the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of NNC0148-0000-0362 in Healthy Subjects